India's supply of antiviral drug remdesivir and generic equivalents is stabilising after shortages of the vital COVID-19 medicine at hospitals, according to a top executive at one of the country's big drugmakers, Cipla Ltd.

India's shortage of Remdesivir is easing, says producer Cipla 

The California-based drug makeing comoany Gilead Sciences has, after numerous months, got a green signal in Hong Kong for the usage of Remdesivir drug against coronavirus.

COVID 19: Gilead's Remdesivir gets a conditional green signal in Hong Kong

The country`s top drug regulator has directed all drug controller in the States and Union Territories to keep strict vigil to prevent the black marketing and sale of the anti-drug Remdesivir injection above the minimum retail price (MRP).

UTs, States told to be vigilant to stop black marketing of Remdesivir

United States in a major move buys almost entire global stock of COVID-19 drug Remdesivir. The US Department of Health and Human Services (HHS) was able to secure more than 500,000 treatment courses.

US buys stocks of anti-viral drug Remdesivir: Europe concerned about US action | DW-WION partnership

The coronavirus pandemic will not end anytime soon. People are learning to live with the pandemic began six months ago. Governments are still hunting for cures. For now, there is no magic bullet.

Coronavirus crisis: United States buys 90 per cent of Remdesivir stock

US buys almost entire global stock of COVID-19 drug remdesivir

The United States has bought almost the entire worldwide stock of the anti-viral drug Remdesivir, which is being considered as a potential cure for coronavirus. As per an announcement made by the US Department of Health and Human Services (HSS) over 500,000 doses of the drug has been bought by the country from its sole manufacturer Gilead Sciences.

US purchases almost entire global stock of potential COVID-19 cure Remdesivir

Gilead Sciences Inc has priced its COVID-19 drug candidate remdesivir at $2,340 for a five-day treatment in the United States and some other developed countries, potentially reflecting looming competition from a cheap steroid.

Gilead gives price tag to first coronavirus drug Remdesivir at $2,340

The European healthcare regulator has recommended the conditional approval of Gilead Sciences Inc’s antiviral treatment, remdesivir, for use in COVID-19 patients.

Remdesivir endorsed as first COVID-19 treatment in Europe

The Health Ministry on Saturday recommended the use of antiviral drug remdesivir in moderate stage of COVID-19 while backtracking from its earlier stance on hydroxychloroquine, saying the anti-malarial drug should be used in the early course of the disease and not on critically ill patients.

Health ministry recommends remdesivir for moderate cases, HCQ for early course of COVID-19

With a rapid increase in the number of coronavirus cases in India, the country is gearing up to start domestic production of the anti-viral Remdesivir drug. The drug will be allowed only for "restricted emergency use" on COVID-19 patients.

COVID 19: India to start domestic production of Remdesivir

6 months, 188 countries, 72 lakh cases and more than 4 lakh deaths. Billions may be emerging from months of lockdown but the virus from Wuhan hasn't disappeared yet.

Remdesivir should be considered for COVID-19 treatment as early as possible: Study

According to the medical journal Nature, medical drug remdesivir can prevent lung disease in macaque monkeys infected by the coronavirus. Its progress in clinical studies is being closely watched. Watch report.

Remdesivir prevents COVID-19 lung damage: Tested on macaque monkeys

The Wuhan virus has infected more than 72,00,000 people across the world. A new study in the Medical Journal Nature says that anti-viral drug Remdesivir can help prevent Lung damage in infected patients. WION's Palki Sharma gets you a report.

Gravitas: Can Remdesivir slow Covid-19 progression?

Gilead Sciences Inc's antiviral drug remdesivir prevented lung disease in macaque monkeys infected with the new coronavirus, according to a study published in the journal Nature on Tuesday.

Gilead's remdesivir prevents lung damage in COVID-19 study on monkeys

South Korea has approved the emergency use of Remdesivir to treat COVID-19 after a government panel last week cited positive results for the anti-viral drug in other countries.

South Korea approves emergency use of Remdesivir to treat COVID-19

After India approved Remdesivir, South Korea on Wednesday issued emergency authorization for the anti-viral drug. Watch Video: The South Korean government said the drug had proved "clinically meaningful" in cutting patients' recovery time.

After India, South Korea approves Remdesivir for coronavirus patients

India has approved Remdesivir for emergency use for five doses in treating COVID-19 patients. Gilead Sciences Inc's antiviral drug, which is administered intravenously in hospital, is the first drug to show improvement in COVID-19 patients in formal clinical trials and is at the forefront of the battle against COVID-19, which has no approved treatment or vaccine.

India approves Remdesivir to treat severe COVID-19 cases

South Korean health authorities said on Friday they would request imports of Gilead Sciences Inc`s anti-viral drug remdesivir to treat COVID-19, as new outbreaks of the disease flare as social distancing restrictions are eased.

South Korea seeks to import anti-viral remdesivir as new coronavirus cases emerge

The Mongolian health ministry has requested for Remdesivir from Indian companies, India's envoy to Mongolia M P Singh has said. Remdesivir though still experimental holds promise in treatment for COVID.

Mongolia requests for Remdesivir used COVID treatment from Indian companies

US pharmaceutical giant Gilead Sciences may soon apply to India's Central Drugs Standard Control Organisation (CDSCO) seeking marketing authorisation for its anti-viral drug remdesivir -- being considered as a potential medication for COVID-19.

US' Gilead Sciences likely to seek nod to market anti-viral drug remdesivir in India

The coronavirus pandemic has killed over 2,80,000 people globally, and several drugmakers are racing to develop a viable treatment or vaccine to combat the outbreak.

Gilead gives royalty-free licences for remdesivir to Indian firms

The Japanese government has decided to authorise remdesivir which is an antiviral drug to treat the coronavirus patients. Also read: Gilead starts clinical trials of Remdesivir with US lawmakers curious about selling price Japan has become the second country after the United States to authorise the drug as an emergency dose to treat the patients in severe cases.

Japan follows United States, authorises remdesivir to help COVID-19 patients in critical stages

Experts in the US say remdesivir is effective in stopping the virus. But, lawmakers want to know how Gilead will price the drug. Will remdesivir be a 'cure' that no one can afford? WION's Palki Sharma brings you an assessment.

Gravitas: Will remdesivir be a 'cure' that no one can afford?

remdesivir

Remdesivir, News on Remdesivir, stories on Remdesivir, articles on Remdesivir, Remdesivir stories at Wion, Remdesivir news, Remdesivir latest news